Aspirin’ beating cancer, stat: prevention has now three agents met-for-mean

Lung cancer is a top death cause worldwide and active prevention by drugs is not perfprmed. Combined use of aspirin, statins, and metformin is associated with decreased lung cancer incidence and mortality, according now to a study published in the Journal of Thoracic Oncology (JTO). The JTO is the official journal of the International Association for the Study of Lung Cancer. All three medications are common–approximately 35 million people take a statin to control cholesterol; more than 120 million people take metformin to control diabetes and between 6 and 10 million people take aspirin daily. The aim of this study was to investigate the associations of aspirin, metformin, and statins with lung cancer risk and mortality using population-based nationwide cohort data from The Korean National Health Insurance Services (KNHIS) database was used in the present study. The KNHIS is a universal health care system that covers the entire Korean population of 50 million. Dr. Shin and his colleagues (Dr. Jihun Kang and Dr. Su-Min Jeong) at the Sungkyunkwan University School of Medicine in Seoul, Korea, examined 732,199 Koreans from the Korean National Health Insurance Services database.

The patients were followed between January 2004 and December 2013. During 2012-2013 period (the most recent period in the study), study participants taking all three medications were 3.4% (23,163 out of 676,520). Lung cancer incidence and mortality were identified using a registered lung cancer diagnosis code (ICD-10 code C34) and the Korean National Death Registry. To address the combined associations of these cardiovascular drugs with lung cancer risk and mortality, the researchers categorized the cohort into eight groups, based on exposure to aspirin, statins, and metformin. Combined use of aspirin, statins, and metformin was associated with decreased lung cancer incidence and mortality compared with non-users. Dr. Shin theorized that concomitant use of aspirin, statins, and metformin concurrently inhibits multiple pathways related to lung cancer cell growth and proliferation resulting in favorable associations with lung cancer risk and mortality. Indeed, statins inhibit the synthesis of cholesterol and a phenomenon called protein prenylation, which allow the correct function of G proteins beneath their receptors.

Metformin is a regulator of the enzyme AMPK, which orchestrates energy metabolism of both carbohydrates and lipids. Aspirin intake, apart its role in cardiovascular health, hs been linked to preventive effects on several forms of cancer, mainly of the digestive apparatus. Moreover, aspirin and metformin synergistically inhibit lung cancer cell proliferation by activating AMP activated protein kinase, which plays a critical role in regulation of lipogenesis in cancer cells. Dong Wook Shin, MD, lead study author commented: “To our knowledge, no study has evaluated aspirin, statins, and metformin use and their combined impact on lung cancer incidence and mortality. When these cardiovascular drugs were used in combination, their protective associations with lung cancer risk and related mortality were augmented and the magnitude of effect increased with increasing duration of medication use. Interestingly, the inverse association of combined use of aspirin, statins, and metformin was prominent, and the longer the duration of combined use, the more protective the association”

  • Edited by Dr. Gianfrancesco Cormaci, PhD, specialist in Clinical Biochemistry.

Scientific references

Cho MH et al. Cancer Prev Res (Phila). 2020 Sep 16.

Sung JJ et al. Cancer Epidemiol 2020 Sep 9; 69:101808.

Shin DW et al. Cancer Epid Biomark Prev. 2020 Aug 31.

Rennert G et al. Diab Res Clin Pract. 2020; 165:108232. 

Informazioni su Dott. Gianfrancesco Cormaci 2479 Articoli
- Laurea in Medicina e Chirurgia nel 1998 (MD Degree in 1998) - Specialista in Biochimica Clinica nel 2002 (Clinical Biochemistry specialty in 2002) - Dottorato in Neurobiologia nel 2006 (Neurobiology PhD in 2006) - Ha soggiornato negli Stati Uniti, Baltimora (MD) come ricercatore alle dipendenze del National Institute on Drug Abuse (NIDA/NIH) e poi alla Johns Hopkins University, dal 2004 al 2008. - Dal 2009 si occupa di Medicina personalizzata. - Detentore di un brevetto sulla preparazione di prodotti gluten-free a partire da regolare farina di frumento immunologicamente neutralizzata (owner of a patent concerning the production of bakery gluten-free products, starting from regular wheat flour). - Responsabile del reparto Ricerca e Sviluppo per la società CoFood s.r.l. (leader of the R&D for the partnership CoFood s.r.l.) - Autore di un libro riguardante la salute e l'alimentazione, con approfondimenti su come questa condizioni tutti i sistemi corporei. - Autore di articoli su informazione medica, salute e benessere sui siti web e